OC
IRD

Oppenheimer & Co’s Opus Genetics IRD Stock Holding History

Oppenheimer & Co’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-56
Closed -$23K – 1498
2014
Q2 		$23K Sell
56
-111
-66% -$50.5K ﹤0.01% 1390
2014
Q1 		$86K Buy
+167
New +$90.3K ﹤0.01% 1351

Other funds holding IRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Oppenheimer & Co's IRD Position: Q3 2014 in Review

Oppenheimer & Co sold out of Opus Genetics (IRD) in Q3 2014, closing a stake of 56 shares — an estimated $23K sold.

Oppenheimer & Co first reported a position in IRD in Q1 2014 and held it in 2 quarters. The position peaked at $86K in Q1 2014. 31 funds tracked by Wall St. Rank hold IRD as of Q3 2014.

  • Oppenheimer & Co reported no remaining Opus Genetics position as of Q3 2014 after selling out during the quarter.
  • Oppenheimer & Co sold 56 Opus Genetics shares in Q3 2014, an estimated $23K.
  • Oppenheimer & Co first reported a position in Opus Genetics in Q1 2014 and held it in 2 quarters.
  • Oppenheimer & Co's Opus Genetics position peaked at $86K in Q1 2014.
  • 31 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2014.

Based on Oppenheimer & Co's 13F filing for Q3 2014, filed 12 Nov 2014.